Concurrent Investment Advisors LLC Acquires 3,675 Shares of CME Group Inc. $CME

Concurrent Investment Advisors LLC increased its holdings in CME Group Inc. (NASDAQ:CME) by 5.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,674 shares of the financial services provider’s stock after acquiring an additional 3,675 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in CME Group were worth $16,711,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Empowered Funds LLC boosted its position in CME Group by 11.5% during the 1st quarter. Empowered Funds LLC now owns 10,027 shares of the financial services provider’s stock valued at $2,660,000 after acquiring an additional 1,037 shares in the last quarter. Marshall Wace LLP raised its position in shares of CME Group by 103.1% in the 2nd quarter. Marshall Wace LLP now owns 3,692 shares of the financial services provider’s stock worth $1,018,000 after acquiring an additional 121,707 shares in the last quarter. Federated Hermes Inc. raised its position in shares of CME Group by 1,325.2% in the 2nd quarter. Federated Hermes Inc. now owns 23,572 shares of the financial services provider’s stock worth $6,497,000 after acquiring an additional 21,918 shares in the last quarter. Nebula Research & Development LLC purchased a new position in shares of CME Group in the 2nd quarter valued at approximately $992,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of CME Group by 2.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 287,876 shares of the financial services provider’s stock valued at $79,344,000 after purchasing an additional 7,397 shares during the period. Institutional investors own 87.75% of the company’s stock.

CME Group Stock Down 0.3%

Shares of CME Group stock opened at $281.29 on Friday. The company has a 50-day simple moving average of $258.76 and a two-hundred day simple moving average of $278.38. The stock has a market capitalization of $101.15 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 3.33 and a beta of 0.24. CME Group Inc. has a 52-week low of $218.31 and a 52-week high of $329.16. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.02 and a current ratio of 1.02.

CME Group (NASDAQ:CME) last posted its quarterly earnings results on Wednesday, July 22nd. The financial services provider reported $2.99 EPS for the quarter, beating analysts’ consensus estimates of $2.91 by $0.08. CME Group had a net margin of 63.30% and a return on equity of 15.60%. The firm had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.68 billion. During the same quarter in the prior year, the company posted $2.96 earnings per share. The business’s revenue for the quarter was up .8% on a year-over-year basis. On average, analysts anticipate that CME Group Inc. will post 12.27 EPS for the current fiscal year.

CME Group Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, September 9th. CME Group’s dividend payout ratio is presently 44.11%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Piper Sandler reduced their price target on CME Group from $329.00 to $295.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 15th. Barclays lowered their price objective on CME Group from $316.00 to $270.00 and set an “equal weight” rating for the company in a research report on Thursday, July 9th. Wall Street Zen upgraded shares of CME Group from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Morgan Stanley increased their price target on shares of CME Group from $324.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Rothschild & Co Redburn raised shares of CME Group from a “neutral” rating to a “buy” rating and lifted their price target for the company from $316.00 to $323.00 in a research report on Thursday, June 11th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $289.75.

Insider Activity

In other CME Group news, Director William Shepard acquired 325 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average cost of $230.57 per share, with a total value of $74,935.25. Following the completion of the transaction, the director directly owned 260,442 shares of the company’s stock, valued at approximately $60,050,111.94. This represents a 0.12% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.30% of the stock is currently owned by insiders.

CME Group Profile

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.